Trypaflavin
Trypaflavin is an acridine compound and antimalarial agent. Trypaflavin invades germ cells. Trypaflavin induces aberrations in unfertilized oocytes. Trypaflavin increases the frequency of chromosomal aberrations. Trypaflavin shows weak mutagenicity. Trypaflavin is highly toxic to Leishmania, causing immediate lysis of the leptomonads.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 86-40-8
- Fòrmula: C14H14ClN3
- Peso molecular:259.73
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Parasite
More
Actividad biológica
|
Leishmania |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
1 μM
Compound: 1
|
Inhibition of HIF-1 dimerization in HEK293 cells after 24 hrs by renilla luciferase reporter gene assay
Inhibition of HIF-1 dimerization in HEK293 cells after 24 hrs by renilla luciferase reporter gene assay
|
[PMID: 30819620] |
Trypaflavin (2 mg/kg/day; p.o.; 50 days) slightly elevates preimplantation egg loss and dead implants without inducing significant dominant lethal mutations in female C3H mice, and weakly increases total chromosome aberration frequencies to 21.1% in metaphase-II oocytes of female NMRI mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H (female; parental generation; pregnant; prenatal in utero treatment to target oogonia/early meiotic oocyte stages); C3H F1 (female; 10 weeks old at mating)
-
Dosage:50 mg/kg
-
Administration:p.o.; single acute dose; day 7, 11, 14, or 15 post conception
-
Result:Induced significant mutagenic effects only with day 7 post conception treatment:
Increased preimplantation egg loss to 24.9%.
Increased dead implants per female to 1.4.
Decreased living embryos per female to 7.2.
Induced dominant lethal mutations of 13.25.
Showed no significant effects with treatment on days 11, 14, or 15 post conception.
-
Animal Model:C3H (female; 3 weeks old at study start)
-
Dosage:2 mg/kg/day
-
Administration:p.o.; daily; 50 days
-
Result:Increased preimplantation egg loss to 13.3%.
Increased dead implants per female to 2.2.
Induced dominant lethal mutations of -1.27.
-
Animal Model:NMRI (female; 3 weeks old at study start)
-
Dosage:2 mg/kg/day
-
Administration:p.o.; daily; at least 50 days
-
Result:Increased the frequency of aberrant metaphase-II oocytes to 21.1%, aneuploidies to 13.5%, structural aberrations including gaps to 9.3%, and structural aberrations excluding gaps to 8.1%.
Increased yield of all aberration types (aneuploidies, gaps, breaks and fragments, satellite associations, deletions, interchanges).
Chemical Information
-
No. CAS 86-40-8
-
Peso molecular 259.73
-
Fòrmula C14H14ClN3
-
SMILES
C[N+]1=C2C=C(N)C=CC2=CC3=C1C=C(N)C=C3.[Cl-]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trypaflavin Related Classifications
HY-B1509A Related Classifications
Powered by Bioz